467 related articles for article (PubMed ID: 26416145)
21. Prognostic markers and standard management of chronic lymphocytic leukemia.
Stilgenbauer S
Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
23. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
24. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
Voorhies BN; Stephens DM
Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
[TBL] [Abstract][Full Text] [Related]
25. The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
Jeyakumar D; O'Brien S
Oncology (Williston Park); 2016 Nov; 30(11):1008-15. PubMed ID: 27854102
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.
Smolej L
Curr Cancer Drug Targets; 2016; 16(8):710-720. PubMed ID: 27055578
[TBL] [Abstract][Full Text] [Related]
27. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
Yeung CCS; Shadman M
Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
[TBL] [Abstract][Full Text] [Related]
28. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
Bachow SH; Lamanna N
Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
[TBL] [Abstract][Full Text] [Related]
29. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
30. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
[TBL] [Abstract][Full Text] [Related]
31. Management of unfit elderly patients with chronic lymphocytic leukemia.
Eichhorst B; Hallek M; Goede V
Eur J Intern Med; 2018 Dec; 58():7-13. PubMed ID: 30527922
[TBL] [Abstract][Full Text] [Related]
32. Targeted Therapy of CLL.
Al-Sawaf O; Fischer K; Eichhorst B; Hallek M
Oncol Res Treat; 2016; 39(12):768-778. PubMed ID: 27889784
[TBL] [Abstract][Full Text] [Related]
33. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
34. New treatment approaches in CLL: Challenges and opportunities in the elderly.
Eichhorst B; Hallek M; Goede V
J Geriatr Oncol; 2016 Sep; 7(5):375-82. PubMed ID: 27491497
[TBL] [Abstract][Full Text] [Related]
35. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
Chaudhry M; Cheson BD
Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
[TBL] [Abstract][Full Text] [Related]
36. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Smolewski P; Robak T
Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
[TBL] [Abstract][Full Text] [Related]
37. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
[TBL] [Abstract][Full Text] [Related]
38. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
40. Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.
Farooqui AA; Ashraf A; Farooq TB; Anjum A; Rehman SU; Akbar A; Kanate A; Dean R; Ahmed MQ; Tariq MJ; Nabeel S; Faisal MS; Anwer F
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e414-e426. PubMed ID: 32291235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]